Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

NCT06646783 is registered in ClinicalTrials.gov with SmartNuclide Biopharma as lead sponsor.

NCT NCT06646783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06646783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of 68GA-labeled Claudin 18.2 Developer Combined with PET/CT for Imaging of Gastric or Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer
Lead sponsor
SmartNuclide Biopharma
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 20, 2024
Completion date
November 20, 2025
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of ge junction, adenocarcinoma of the stomach, pancreatic cancer stage